- Home
- UFCS vs ORIC Comparison
UFCS vs ORIC Comparison
Compare UFCS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- ORIC
- Stock Information
- Founded
- UFCS 1946
- ORIC 2014
- Country
- UFCS United States
- ORIC United States
- Employees
- UFCS N/A
- ORIC N/A
- Industry
- UFCS Property-Casualty Insurers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- ORIC Health Care
- Exchange
- UFCS Nasdaq
- ORIC Nasdaq
- Market Cap
- UFCS 666.1M
- ORIC 362.9M
- IPO Year
- UFCS N/A
- ORIC 2020
- Fundamental
- Price
- UFCS $27.12
- ORIC $11.10
- Analyst Decision
- UFCS Buy
- ORIC Strong Buy
- Analyst Count
- UFCS 2
- ORIC 9
- Target Price
- UFCS $30.00
- ORIC $18.29
- AVG Volume (30 Days)
- UFCS 128.8K
- ORIC 949.2K
- Earning Date
- UFCS 08-05-2025
- ORIC 08-11-2025
- Dividend Yield
- UFCS 2.35%
- ORIC N/A
- EPS Growth
- UFCS N/A
- ORIC N/A
- EPS
- UFCS 2.54
- ORIC N/A
- Revenue
- UFCS $1,288,423,000.00
- ORIC N/A
- Revenue This Year
- UFCS $11.31
- ORIC N/A
- Revenue Next Year
- UFCS $10.61
- ORIC N/A
- P/E Ratio
- UFCS $10.74
- ORIC N/A
- Revenue Growth
- UFCS 14.59
- ORIC N/A
- 52 Week Low
- UFCS $18.04
- ORIC $3.90
- 52 Week High
- UFCS $31.70
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- UFCS 38.82
- ORIC 66.82
- Support Level
- UFCS $27.46
- ORIC $10.42
- Resistance Level
- UFCS $28.35
- ORIC $11.50
- Average True Range (ATR)
- UFCS 0.65
- ORIC 0.62
- MACD
- UFCS -0.13
- ORIC -0.03
- Stochastic Oscillator
- UFCS 8.17
- ORIC 83.30
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.